EVOLVE: Cinacalcet fails to reduce death or cardiovascular events

The trial was based on the hypothesis that secondary hyperparathyroidism in patients with chronic kidney disease may contribute to vascular calcification and that the calcimimetic agent cinacalcet might reduce CV risk.

via The Heart